MRKR
MARKER THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $3.80 | $1.39 | -63% |
| Two Sigma Investments | Q4 2025(8Q snapshot) | 2Q | $0.92 | $1.39 | +51% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q1 2026 | Q2 2026 | → $1.42 | -2% |
| Millennium Management | Q1 2025 | Q2 2025 | → $1.13 | -34% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Marker Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Nov 19, 2025 — the most recent Form 4 on file — not from today.
- Form 40001768011-25-000003Nov 19, 2025
- Form 40001270905-25-000003Nov 19, 2025
- Form 40001104659-25-114081Nov 19, 2025
- Form 40001884123-25-000010Nov 4, 2025
- Form 40001755495-25-000003Nov 4, 2025
- Form 40001104659-25-014321Feb 14, 2025
- Form 40001104659-25-014318Feb 14, 2025
- Form 40001104659-25-014317Feb 14, 2025
- Form 40001104659-25-014315Feb 14, 2025
- Form 40001104659-24-131704Dec 26, 2024
- Form 40000950170-24-139630Dec 23, 2024
- Form 40001209191-23-035617Jun 8, 2023
- Form 40001209191-23-035616Jun 8, 2023
- Form 40001209191-23-035615Jun 8, 2023
- Form 40001209191-23-035614Jun 8, 2023
Fundamentals
XBRL · MARKER THERAPEUTICS, INC.Annual figures sourced directly from MARKER THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Marker Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 15, 2026
- 8-KFORM 8-KMay 4, 2026
- DEF 14AFORM DEF 14AMar 20, 2026
- 8-KFORM 8-KMar 19, 2026
- 10-KAnnual reportMar 18, 2026
- 8-KFORM 8-KFeb 9, 2026
- 8-KFORM 8-KNov 14, 2025
- 10-QQuarterly reportNov 13, 2025
- 8-KFORM 8-KNov 5, 2025
- 8-KFORM 8-KOct 6, 2025
- 8-KFORM 8-KAug 26, 2025
- 10-QQuarterly reportAug 14, 2025
- 8-KFORM 8-KAug 12, 2025
- 8-KFORM 8-KJun 17, 2025
- 8-KFORM 8-KJun 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | Q2 2026 | $1.45 | $1.42 | -2% |
| Two Sigma Investments | Q4 2025 | open | $0.92 | $1.39 | +51% |
| Millennium Management | Q1 2025 | Q2 2025 | $1.72 | $1.13 | -34% |
| Citadel Advisors | Q4 2024 | Q1 2025 | $3.50 | $1.72 | -51% |
| Renaissance Technologies | Q3 2024 | open | $3.80 | $1.39 | -63% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.